SCHEMBL21299147

SCHEMBL21299147

BOc1ccccc1-c1cccc(-c2ccccn2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 8/20 0.60
▸ TP53 P04637 8/20 0.60
▸ KDM4E B2RXH2 7/20 0.60
▸ CCR1 P32246 3/20 0.60
▸ CCR5 P51681 3/20 0.60
▸ CCR8 P51685 3/20 0.60
▸ LMNA P02545 3/20 0.60
▸ ALOX15 P16050 3/20 0.60
▸ L3MBTL1 Q9Y468 3/20 0.60
▸ HTT P42858 2/20 0.60
▸ TDP1 Q9NUW8 2/20 0.60
▸ MAPK1 P28482 2/20 0.60
▸ ALPL P05186 1/20 0.60
▸ HSP90AA1 P07900 1/20 0.60
▸ ALPI P09923 1/20 0.60
▸ ALPG P10696 1/20 0.60
▸ CYP1A2 P05177 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ METAP1 P53582 1/20 0.47
▸ BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18976884 0.88 KDM4E (0.50) SMN1; SMN2TP53KDM4ECCR1CCR5
SCHEMBL5681545 0.83 SMN1; SMN2 (0.60) SMN1; SMN2TP53KDM4ECCR1CCR5
SCHEMBL18654155 0.83 KDM4E (0.60) SMN1; SMN2TP53KDM4ECCR1CCR5
SCHEMBL7964803 0.78 KDM4E (1.00) SMN1; SMN2TP53KDM4ECCR1CCR5
SCHEMBL30172832 0.78 KDM4E (1.00) SMN1; SMN2TP53KDM4ECCR1CCR5
Terpyridine SCHEMBL29357603 0.78 KDM4E (1.00) SMN1; SMN2TP53KDM4ECCR1CCR5
Terpyridine SCHEMBL57442 0.78 KDM4E (1.00) SMN1; SMN2TP53KDM4ECCR1CCR5
SCHEMBL993751 0.76 KDM4E (0.78) SMN1; SMN2TP53KDM4ECCR1CCR5
Terpyridine SCHEMBL1616654 0.75 KDM4E (0.95) SMN1; SMN2TP53KDM4ECCR1CCR5
Terpyridine SCHEMBL7112915 0.75 KDM4E (0.95) SMN1; SMN2TP53KDM4ECCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10396293-B2 Electronic or optoelectronic device comprising an anchored thin molecular layer, process for its preparation and compound used therein NOVALED GMBH (DE) 2019-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10396293-B2 Electronic or optoelectronic device comprising an anchored thin molecular layer, process for its preparation and compound used therein EPCAM, OR10J3, OR51E2 SMN1; SMN2 4655/4885TP53 4818/4885KDM4E 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback